ICICI Securities remains constructive on Archean Chemical, GSK Pharma, MakeMyTrip and Nexus Select, citing improving earnings visibility, growth investments, market-share gains and sustained demand trends across sectors.
ICICI Securities remains constructive on Archean Chemical, GSK Pharma, MakeMyTrip and Nexus Select, citing improving earnings visibility, growth investments, market-share gains and sustained demand trends across sectors.
<iframe src="https://hindustansphere.com/embed/cluster/4e293d29a958e7a2ee441e2563d72a4752fc5e20" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="From GSK Pharma To MakeMyTrip: ICICI Securities Highlights Key Post-Q1 Opportunities"></iframe>
